#United States #AbbVie #North Chicago #EHA 2026 #hematologic cancer

AbbVie Showcases Hematologic Cancer Advances at EHA 2026

On June 8, 2026, AbbVie (NYSE: ABBV) made significant strides in oncology by presenting new data at the European Hematology Association (EHA) 2026 annual meeting. This year's conference highlighted insights into multiple hematologic cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML), and light chain amyloidosis (AL).

The presentations included six oral presentations showcasing AbbVie's leadership and ongoing commitment to research and development aimed at improving patient outcomes for those facing blood cancers. With a focus on innovative solutions, these studies underline the urgency of elevating the standard of care in hematologic malignancies.

Dr. Daejin Abidoye, Vice President and Head of Oncology, Solid Tumor, and Hematology at AbbVie, expressed: "The compelling data we present at EHA reflects our unwavering portfolio and pipeline, as well as our ongoing efforts to deepen the understanding and treatment of hematologic cancers. With this research, we continue to work on innovative solutions that could raise the bar in standard treatment and address pressing challenges."

Key Highlights from EHA

Epcoritamab Data Presentations

One of the standout portions of AbbVie’s presentation was dedicated to the efficacy of epcoritamab, particularly in re-treated or refractory patients with FL. A subgroup analysis from the phase 3 EPCORE FL-1 trial revealed substantial clinical responses when epcoritamab was administered with rituximab and lenalidomide (E+R2 therapy).

• - The overall response rate (ORR) in high-risk patient categories demonstrated remarkable efficacy with E+R2 therapy compared to conventional R2 therapy: 96.5% vs 84.8% among patients with FLIPI scores of 0-2, illustrating the treatment’s robustness across varying patient profiles.
• - This trend held for patients experiencing progression of disease within two years since the initiation of treatment.

In another trial focused on DLBCL, preliminary data from the randomized phase 3 EPCORE DLBCL-1 study showed that the epcoritamab monotherapy statistically improved progression-free survival (PFS) compared to selected immunochemotherapy regimens, spending notable moments during the meeting discussing safety profiles and efficacy comparisons across diverse demographics.

Comparative Studies on Venetoclax

AbbVie also shared findings from clinical trials involving venetoclax-based therapies for CLL patients. Insights from the GAIA/CLL13 trial presented genetic biomarkers proficiently predicting treatment efficacy. The analysis reaffirmed that patient profiles without specific genetic anomalies showed promising outcomes when treated with the combination therapy of venetoclax and rituximab.

Innovation with Etentamig

Etentamig (ABBV-383), still under investigation, was another crucial focus. AbbVie's safety and efficacy evaluations in trials involving patients with relapsed/refractory multiple myeloma and light chain amyloidosis underscored the importance of continued clinical research. While these treatments have yet to achieve regulatory approvals in Europe, the data yielded are likely to shape future approvals and treatment protocols:

• - Results from ongoing trials indicated promising long-term efficacy and safety data that will be critical as they advance through development.

Pivekimab Sunirine-Pvzy's Emerging Role

Pivekimab sunirine-pvzy's use in blastic plasmacytoid dendritic cell neoplasm (BPDCN) also represented groundbreaking work discussed in the cad program. The latest analysis of the CADENZA trial emphasized significant efficacy data related to various eligibility criteria and disease baseline characteristics.

Looking Forward

The 2026 EHA meeting brought to light AbbVie’s commitment and positions within the oncology community. With a comprehensive portfolio combining a blend of already-approved treatments and promising investigational therapies, AbbVie is paving the way toward better patient outcomes in the often complex landscape of hematologic cancers. Additional insights into these trials can be explored further on clinicaltrials.gov.

In its ongoing mission, AbbVie persists in tackling severe health challenges through innovative medical solutions. With a focus on improving lives across various therapeutic categories such as oncology, immunology, and neurology, AbbVie remains a key player in enhancing patient care and treatment paradigms—continuously striving for a future where the burden of cancer is significantly alleviated. For more details on AbbVie’s oncology initiatives, visit AbbVie Oncology.